{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-020460","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2024-05-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.247432+00:00","generated_at":"2026-06-01T15:55:57.645101+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BriaCell raises $5.0M in registered direct offering with warrants; director participates","bullets":["Gross proceeds of $5.0M from sale of 2,402,935 shares (or pre-funded warrants) and warrants for additional 2,402,935 shares.","Combined purchase price: $2.00/share for institutional investors; $2.215/share for a director of the company.","Warrants exercisable at $2.11/share, beginning 6 months from issuance, expiring in 5 years.","Net proceeds to fund working capital and Phase 3 pivotal study in advanced breast cancer.","Closing occurred May 17, 2024; placement agent A.G.P./Alliance Global Partners received 7% fee and 50,000 warrants."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-020460","json":"https://secwatch.observer/filing/0001493152-24-020460.json","markdown":"https://secwatch.observer/filing/0001493152-24-020460.md","text":"https://secwatch.observer/filing/0001493152-24-020460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T15:55:57.645101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"563f5daf1459d3ba224d4ab6f7a7030acfe54727","claim":"BriaCell Therapeutics Corp. entered into Securities Purchase Agreements with certain investors valued at Gross proceeds of $5,000,000 from sale of shares and warrants (effective 2024-05-14).","evidence_excerpt":"On May 14, 2024, BriaCell Therapeutics Corp. (the “Company”) entered into securities purchase agreements (the “Purchase Agreements”) with certain investors (collectively the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"Gross proceeds of $5,000,000 from sale of shares and warrants"},{"label":"Effective","value":"2024-05-14"}],"fact_type":"material_agreement"},{"claim_id":"7abf9be44a86a0812102d79e97a183fdc34aacf6","claim":"BriaCell Therapeutics Corp. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share (effective 2024-05-14).","evidence_excerpt":"In connection with the Offering, on May 14, 2024, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with A.G.P./Alliance Global Partners (the “Placement Agent”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315224020460/0001493152-24-020460-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"A.G.P./Alliance Global Partners"},{"label":"Value","value":"Cash fee of 7.0% of gross proceeds; Placement Agent Warrants for 50,000 shares at $2.321 per share"},{"label":"Effective","value":"2024-05-14"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}